Amgen Inc. (NASDAQ:AMGN – Free Report) – Research analysts at Erste Group Bank increased their FY2026 EPS estimates for Amgen in a report released on Thursday, August 27th. Erste Group Bank analyst H. Engel now expects that the medical research company will post earnings of $23.05 per share for the year, up from their previous estimate of $22.41. Erste Group Bank has a “Hold” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $22.97 per share.
A number of other brokerages have also recently commented on AMGN. Piper Sandler upped their price target on Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Argus boosted their price objective on Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. TD Cowen boosted their price objective on Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Cantor Fitzgerald upped their price objective on shares of Amgen from $350.00 to $400.00 and gave the company a “neutral” rating in a report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $380.43.
Amgen Price Performance
Shares of NASDAQ AMGN opened at $429.88 on Monday. The stock has a fifty day simple moving average of $390.35 and a two-hundred day simple moving average of $365.09. Amgen has a 1-year low of $269.77 and a 1-year high of $447.03. The firm has a market cap of $232.41 billion, a price-to-earnings ratio of 26.72, a price-to-earnings-growth ratio of 3.12 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.
Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the prior year, the firm earned $6.02 EPS. The company’s revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Cornerstone Financial Management LLC increased its holdings in Amgen by 7.2% during the 2nd quarter. Cornerstone Financial Management LLC now owns 459 shares of the medical research company’s stock worth $166,000 after acquiring an additional 31 shares during the period. HORAN Wealth LLC boosted its holdings in Amgen by 1.9% in the 2nd quarter. HORAN Wealth LLC now owns 15,478 shares of the medical research company’s stock valued at $5,605,000 after purchasing an additional 284 shares during the period. Amundi boosted its holdings in Amgen by 15.2% in the 2nd quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock valued at $1,408,715,000 after purchasing an additional 512,883 shares during the period. Groupe la Francaise grew its position in shares of Amgen by 647.8% during the 2nd quarter. Groupe la Francaise now owns 1,361 shares of the medical research company’s stock valued at $493,000 after purchasing an additional 1,179 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Amgen during the 2nd quarter valued at $29,326,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Insiders Place Their Bets
In related news, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 6,222 shares of company stock valued at $2,540,926 over the last ninety days. Corporate insiders own 0.85% of the company’s stock.
Amgen Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is presently 62.65%.
More Amgen News
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Repatha demonstrated a meaningful mortality benefit. Amgen reported that Repatha reduced the risk of death by 20% in more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. The findings came from a prespecified analysis of the Phase 3 VESALIUS-CV trial presented at the 2026 European Society of Cardiology Congress. The result could support broader use of Repatha beyond cholesterol reduction and strengthen one of Amgen’s key revenue drivers. Amgen Repatha clinical results
- Positive Sentiment: Analyst sentiment and performance comparisons remain supportive. Commentary says AMGN has outperformed the broader market over the past year, with analysts moderately bullish on its future prospects. Erste Group Bank also issued a positive forecast for Amgen’s earnings, adding to the favorable outlook. Amgen stock performance comparison
- Neutral Sentiment: Industry growth could provide a secondary opportunity. A new report identifies Amgen among companies participating in the expanding palmoplantar pustulosis market, driven by increased diagnosis and demand for biologic treatments. However, the report does not identify a specific Amgen product or provide a material revenue forecast, so the immediate stock impact is likely limited. Palmoplantar pustulosis market report
Amgen Company Profile
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Articles
- Five stocks we like better than Amgen
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
